Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors
- 1 June 1995
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Investigational New Drugs
- Vol. 13 (2), 163-165
- https://doi.org/10.1007/bf00872866
Abstract
Fifteen patients with advanced, cisplatin-refractory germ cell tumors (GCT) were treated on a phase II trial with topotecan. None of the 14 evaluable patients achieved a complete or partial response. Myelosuppression was the major toxicity. The median nadir leukocyte count was 1.75 cells/mm3, neutrophil count was 1.55 cells/mm3, hemoglobin was 8.75 gm/dl, and platelet count was 20,500 cells/mm3. Topotecan is not efficacious in the treatment of cisplatin-refractory GCT.Keywords
This publication has 5 references indexed in Scilit:
- Computerized Quantitation of Synergism and Antagonism of Taxol, Topotecan, and Cisplatin Against Human Teratocarcinoma Cell Growth: a Rational Approach to Clinical Protocol DesignJNCI Journal of the National Cancer Institute, 1994
- Phase I Clinical and Pharmacology Study of Topotecan Given Daily for 5 Consecutive Days to Patients With Advanced Solid Tumors, With Attempt at Dose Intensification Using Recombinant Granulocyte Colony-Stimulating FactorJNCI Journal of the National Cancer Institute, 1993
- The Current Status of Camptothecin Analogues as Antitumor AgentsJNCI Journal of the National Cancer Institute, 1993
- Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity.1989
- Reporting results of cancer treatmentCancer, 1981